You have no items in your shopping cart.



Manufacturer: Fidia
Active Substance(s) : Hyaluronan
Strength: 24mg/3ml
Pack Size: 2-3ml prefilled syringes
Accessories: Package insert
You can save $60.00 if you add an additional 5 units to your cart.

Product Specification

Hymovis is a sterile, viscoelastic hydrogel. It consists of ultra-pure hyaluronan (hyaluronic acid) known as HYADD 4, which is made using a proprietary process to increase viscosity, elasticity, and residence time without chemical crosslinking. What this means to patients is that Hymovis can act as an effective viscosupplement to be used for treatment of pain in patients diagnosed with osteoarthritis of the knee. Hymovis is suitable to be given once more conventional conservative therapies or simple analgesic medications have failed to deliver pain relief. Hymovis is delivered into the knee via a two-injection regimen in the affected knee; the second injection should be given a week after the first one. Hymovis can be given to both knees if needed. Hymovis should only be injected by a medical professional with relevant experience since its administration requires skill, experience, and technical knowledge. Hymovis is a prescription-only medication.

What Hymovis is Formulated to Do

Hymovis is formulated to treat knee pain related to osteoarthritis pain for patients who have failed to respond to simple painkillers and conventional therapy. It is injected into the affected knee to exert its desired effects. When injected into an affected knee, Hymovis is clinically proven to deliver pain relief for up to six months.


Hymovis is manufactured by Fidia Farmaceutici S.p.A., which is a medical company that is based in Italy.


Hymovis originates from Italy.

What Else You Need to Know

What side effects can it cause?

Hymovis can potentially cause side effects such as infection, arthrosis, joint disorder, arthropathy, Baker’s Cyst, and bursitis. More common side effects are joint pain, joint swelling, joint effusion, joint stiffness, tendonitis, injection site reactions, and the risk of aggravating the osteoarthritis. More systemic side effects that have been reported with the use of Hymovis include rash, headache, dizziness, chills, nausea, muscle cramps, and malaise. It is recommended that patients avoid strenuous or prolonged physical activities for 48 hours after treatment to minimize the risk of side effects occurring.

Which skin type is it good for?

Hymovis is suitable for any skin type.

What is it made without?

Hymovis is made of hyaluronan and does not contain any other medications, such as antibiotics, anti-inflammatory drugs, or steroids.

Information about packaging

Hymovis is supplied in syringes that are sterile and non-pyrogenic. The components of these syringes do not have latex.

Is Hymovis FDA approved?

The FDA approved Hymovis in 2015 for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond to conservative treatment or simple analgesics.

What are the differences between Fidia Farmaceutici S.p.A. products?

Hymovis is the sole medication sold by Fidia Farmaceutici S.p.A. It does not make other competing products.

Suggested Usage

Hymovis is only meant to be injected into the knee joint. It is administered via two intra-articular injections. Prepare the injection site in accordance with strict aseptic protocols. Do not use quaternary ammonium salts for skin preparation, as it can cause the hyaluronan component to precipitate. Use an 18–20 gauge needle. Remove or aspirate synovial fluid or effusion prior to injecting Hymovis. Use a different syringe for removing fluid or effusion and for injecting Hymovis so as to not contaminate the syringes. Remove the protective rubber cap at the tip of the syringe by twisting it before pulling it off to minimize product leakage. After that is done, attach the needle onto the tip. The needle should be secured tightly by holding the luer hub during attachment. Do not rotate the hub during needle attachment, as it can cause the loosening of the hub. Do not overtighten or apply excessive leverage during attachment. Do not remove the needle guard, as this can break the syringe tip. Inject the full 3ml dose from one syringe in one knee only. If the other knee also requires treatment, repeat the steps above with another syringe. The second injection should be administered one week after the first injection in the same manner.


Hymovis consists of 8mg/ml of hyaluronan (HYADD 4) that is dissolved in physiologic saline. Each 5ml syringe that comes in a package of Hymovis contains 3ml of the viscosupplement. HYADD 4 is a modified form of hyaluronic acid that is developed via a proprietary process that does not involve chemical cross-linking and results in Hymovis being a highly viscoelastic hydrogel. It has increased lubricating and shock absorption properties that make it suitable to be used for osteoarthritis of the knee. The hyaluronic acid component is derived from the bacterial fermentation of Streptococcus equi.

What is in a Box of this Product?

A box of this product comes with a package insert and two single-use 5ml syringes that each contain a 3ml dose of Hymovis (8mg/ml of hyaluronan (HYADD 4) that is dissolved in physiologic saline).

Duration of Effect

Studies shown that the pain-relieving effects of Hymovis can last for six months after the viscosupplement is injected.

Storage Conditions

Hymovis must be stored in its original packaging at room temperature (below 25ºC). Do not freeze it.

Expiry Shelf Life

Hymovis can be expected to last for a few years after it is manufactured. For more details on the expiration date of Hymovis, please refer to its original packaging. Do not inject Hymovis after it has expired.